Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



ArQule Plunges 50%, What's Next?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Shares in ArQule (Nasdaq: ARQL  ) are down more than 50% this morning following a press release announcing the discontinuation of phase 3 trials for tivantinib in the treatment of non-small-cell lung cancer.

This isn't surprising news when you consider recent negative events. At the end of August, Kyowa Hakko Kirin Co. -- the company holding development rights for tivantinib in Japan and parts of Asia -- suspended its own phase 3 trial after its safety review committee investigated patients suffering from interstitial lung disease while on the drug. While this wasn't the ultimate reasoning for the suspension of the trial run by ArQule and partner Daiichi Sankyo group, it certainly raised some red flags.

According to the press release, the reasoning for this stoppage has to do with efficacy. After an interim review by an independent Data Monitoring Committee, it was found that the overall survival benefit for patients receiving a combination of tivantinib and Roche's (NASDAQOTH: RHHBY  ) erlotinib wasn't significant enough to merit continuing trials. Oddly enough, benefits in progression-free survival were statistically significant, but didn't transfer over to overall survival.

This is a critical blow for ArQule, as tivantinib was its only late stage pipeline candidate. While the company has four other programs in place, all are in phase 1 or pre-clinical stages. The only saving grace for the company is cold hard cash. With $75 million of cash on the balance sheet as of last quarter, ArQule has some time to figure out the next steps. Unfortunately, options appear limited at this juncture.

With biotech stocks, the potential for huge gains can come with a lot of volatility. For some steadier companies that the market hasn't uncovered yet, check out The Motley Fool's free report "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice." It's free for a limited time, so click here to download your copy today!

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2040227, ~/Articles/ArticleHandler.aspx, 10/20/2016 8:41:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/20/2016 4:00 PM
ARQL $1.42 Down -0.03 -2.07%
ArQule CAPS Rating: ***
RHHBY $29.23 Down -0.22 -0.75%
Roche Holding Ltd.… CAPS Rating: *****